Delivery Order SPE2DB20D3104-SPE2DB24FV8Z9

Award Date 8/26/24
Potential Completion Date 8/27/24
Potential Value $6.3K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,100.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the medication LINZESS 145 MCG CAPSULE UU 30S, with a performance period ending on April 24, 2025. The contract is a Firm Fixed Price agreement, without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
This federal contract award, valued at $3,844.55, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product. The contract has an ultimate completion date of November 26, 2024 and is a Firm Fixed Price arrangement. It is not designated as a set-aside contract. AmerisourceBergen holds a significant...
This federal contract award, valued at $2,876.50, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 145 MCG Capsules, a type of prescription medication, to support medical needs across DLA's operations. The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of July 17, 2024. It is not designated as a set-aside contract,...
This federal contract award, valued at $1,988.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 145 MCG CAPSULE UU 30S, a pharmaceutical product, with a completion date of September 27, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,280.72 firm fixed-price contract is for the delivery of LINZESS 145 MCG CAPSULE UU 30S, a prescription medication. The contract has an ultimate completion date of June 24, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop...
This federal contract award, valued at $1,654.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 290 MCG CAPSULE, a pharmaceutical product. The contract has an ultimate completion date of December 30, 2024, and is a Firm Fixed Price Delivery Order. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant...
This federal contract award, valued at $1,891.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 72 MCG CAPSULE UU 30S, a pharmaceutical product, with a performance period extending through May 12, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a...
This federal contract award, valued at $11,328.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,567,968,141 units of the medication LINZESS 145 MCG CAPSULE. The contract has a firm fixed price and an ultimate completion date of April 21, 2025. This award is not associated with a set-aside program and appears to be an open competition contract....
This federal contract award, valued at $1,507.20, was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 145 MCG capsules, a medication used in the treatment of various medical conditions. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which...
This federal contract award, valued at $3,095.61, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of LINZESS 72 MCG CAPSULE UU 30S, a pharmaceutical product. This is a firm-fixed-price delivery order contract with a completion date of July 17, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
  • SPE2DB20D3104
    Indefinite Delivery Contract
  • SPE2DB20D3104-SPE2DB24FV8Z9
    Delivery Order

This federal contract award, valued at $6,328.69, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of LINZESS 145 MCG CAPSULE UU 30S, a prescription medication.

The contract is a Firm Fixed Price Delivery Order, with an ultimate completion date of August 27, 2024. It is not designated as a set-aside contract. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. Additionally, the company maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, covering similar medical products and prescription drugs.

Generated 2/27/25, 9:50 AM